Myovant Sciences ROA 2017-2022 | MYOV

Current and historical return on assets (ROA) values for Myovant Sciences (MYOV) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Myovant Sciences ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $-0.17B $0.46B -29.15%
2022-03-31 $-0.21B $0.52B -32.54%
2021-12-31 $-0.23B $0.60B -33.32%
2021-09-30 $-0.24B $0.68B -32.89%
2021-06-30 $-0.28B $0.73B -48.07%
2021-03-31 $-0.26B $0.73B -57.89%
2020-12-31 $-0.24B $0.77B -83.64%
2020-09-30 $-0.25B $0.14B -201.20%
2020-06-30 $-0.26B $0.13B -186.47%
2020-03-31 $-0.29B $0.11B -172.88%
2019-12-31 $-0.30B $0.13B -162.60%
2019-09-30 $-0.29B $0.18B -140.74%
2019-06-30 $-0.28B $0.25B -141.06%
2019-03-31 $-0.27B $0.17B -157.25%
2018-12-31 $-0.25B $0.20B -153.65%
2018-09-30 $-0.22B $0.17B -150.60%
2018-06-30 $-0.18B $0.15B -133.09%
2018-03-31 $-0.14B $0.12B -102.88%
2017-12-31 $-0.12B $0.14B -75.24%
2017-09-30 $-0.08B $0.14B -48.97%
2017-06-30 $-0.09B $0.16B -64.71%
2017-03-31 $-0.08B $0.19B -87.96%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.600B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00